ProPhase Labs Inc.

0.44
-0.01 (-1.15%)
At close: Jan 28, 2025, 2:01 PM

Company Description

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States.

The company operates in two segments, Diagnostic Services and Consumer Products.

It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services.

It serves national chain drug, internet-based, and various regional retailers.

The company was formerly known as The Quigley Corporation.

ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs Inc.
ProPhase Labs Inc. logo
Country United States
IPO Date Apr 4, 1994
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 113
CEO Ted William Karkus

Contact Details

Address:
711 Stewart Avenue
Garden City, New York
United States
Website https://www.prophaselabs.com

Stock Details

Ticker Symbol PRPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000868278
CUSIP Number 74345W108
ISIN Number US74345W1080
Employer ID 23-2577138
SIC Code 2834

Key Executives

Name Position
Ted William Karkus Chairman & Chief Executive Officer
Jed A. Latkin Chief Operating Officer & Head of Finance Department
Sergio Miralles Executive Vice President & Chief Information Officer
Jason Karkus President of Nebula Genomics
Kamal Obbad Senior Vice President and Director of Sales & Marketing - Nebula Genomics
Lance Bisesar Corporate Controller

Latest SEC Filings

Date Type Title
Jan 23, 2025 8-K Current Report
Dec 27, 2024 8-K Current Report
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 NT 10-Q Filing
Nov 13, 2024 8-K Current Report
Nov 12, 2024 S-3 Filing
Nov 08, 2024 424B5 Filing
Nov 07, 2024 8-K Current Report
Nov 07, 2024 424B5 Filing
Oct 18, 2024 8-K Current Report